Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Oct 1;17(19):6112-7.
doi: 10.1158/1078-0432.CCR-11-1073. Epub 2011 Aug 15.

New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice

Jonathan W Friedberg  1
Affiliations
Review

New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice

Jonathan W Friedberg. Clin Cancer Res. .

Abstract

Gene expression profiling has had a major impact on our understanding of the biology and heterogeneity of diffuse large B-cell lymphoma (DLBCL). Using this technology, investigators can identify biologic subgroups of DLBCL that provide unique targets for rational therapeutic intervention. This review summarizes these potential targets and updates the progress of clinical development of exciting novel agents for the treatment of DLBCL. Results of ongoing studies suggest that in the near future, we will be able to use gene expression profiling, or an accurate surrogate, to define the best therapeutic approach for individual patients with DLBCL.

PubMed Disclaimer

Figures

Figure 1
Figure 1. B-cell receptor (BCR) pathway members and Protein Kinase C as potential targets in treatment of DLBCL
Abbreviations: Syk: spleen tyrosine kinase; BTK: Bruton’s tyrosine kinase; PI3K: phosphatidylinositol 3 kinase; PKC: protein kinase C beta; GSK3: glycogen synthase kinase.
See this image and copyright information in PMC

References

    1. Friedberg JW, Fisher RI. Diffuse large B-cell NHL. Cancer Treat Res. 2006;131:121–140. - PubMed
    1. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002–1006. - PubMed
    1. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 116:2040–2045. - PMC - PubMed
    1. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Lancet Oncol. 2008;9:105–116. - PubMed
    1. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027–5033. - PubMed

Publication types